TIROCAP CAPSULE

Country: Canada

Language: English

Source: Health Canada

Buy It Now

Active ingredient:

LEVOTHYROXINE SODIUM

Available from:

IBSA INSTITUT BIOCHIMIQUE SA

ATC code:

H03AA01

INN (International Name):

LEVOTHYROXINE SODIUM

Dosage:

88MCG

Pharmaceutical form:

CAPSULE

Composition:

LEVOTHYROXINE SODIUM 88MCG

Administration route:

ORAL

Units in package:

100

Prescription type:

Prescription

Therapeutic area:

THYROID AGENTS

Product summary:

Active ingredient group (AIG) number: 0107794006; AHFS:

Authorization status:

APPROVED

Authorization date:

2021-06-21

Summary of Product characteristics

                                _TIROCAP™ (levothyroxine sodium capsules) _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TIROCAP™
Levothyroxine Sodium capsule
Capsules,13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125
mcg,
137 mcg, 150 mcg, 175 mcg and 200 mcg, oral
Thyroid Hormone
ATC Code: H03AA01
Institut Biochimique SA (IBSA)
Via del Piano 266
CH-6915 Pambio-Noranco,
Switzerland
Imported by:
Progress Therapeutics Inc.
14-320 Harry Walker Parkway North
Newmarket ON
Canada, L3Y 7B4
Date of Initial Authorization:
November 25, 2020
Date of Revision:
June 17, 2021
Submission Control No: 248553
_ _
_TIROCAP™ (levothyroxine sodium capsules) _
_Page 2 of 32_
TABLE OF CONTENTS
TABLE OF
CONTENTS.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................. 5
4
DOSAGE AND ADMINISTRATION
.........................................................................
5
4.1
Dosing
Considerations.....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................. 6
4.3
Administration...................................................................................................
9
4.4
Missed
Dose.....................................................................................................
9
5
OVER
                                
                                Read the complete document
                                
                            

Documents in other languages

Search alerts related to this product